De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal

University of Rome Tor Vergata92 enrolled

Overview

Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those taking immunosuppressive therapy ("non-tolerant").

A retrospective single-center study was conducted aiming to define the incidence of de novo Metabolic Syndrome (MS) in patients who withdraw Immunosoppression (IS) drugs after Liver Transplant (Tolerant-group) compared to these who couldn't wean IS drugs(non-TOL-group).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Single Transplant 5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS

Interventions

ImmunosuppressiveDRUG

compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.

Eligibility

Sex: ALLMin age: 49 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: * single LT recipients with an attempt of IS withdrawal * minimum 5 years follow-up Exclusion Criteria: * Liver transplant combined with other organs * Presence of metabolic syndrome and/or NASH and/or NAFLD as an indication for liver transplantation * Loss of patient to follow-up

Locations (1)

Roberta Angelico

Rome, Italy

Outcomes

Primary Outcomes

relation between MS development and IS in LT recipients

Evaluate the de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those who could not withdraw IS ("non-tolerant").

Time frame: 5 years

Secondary Outcomes

IS withdrawal in LT recipients

Evaluate the clinical course of patients undergoing discontinuation of immunosuppressive therapy

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.